文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

子宫内膜癌中与脓毒症相关的免疫标志物C3:通过生物信息学和实验验证对预后及肿瘤进展的影响

Sepsis-related immune signature C3 in endometrial carcinoma: implications for prognosis, tumor progression through bioinformatics and experimental validation.

作者信息

Ali Wajahat, Ahmad Saleem, Khan Irfan Ali, Soni Tanveen Kaur, Masood Asia, Iqbal Muhammad Omer, Uglu Valisher Sapayev Odilbek, Djumaniyazova Mukhayya Xusinovna, Cholavaram Anas Sameed, Abdulrahmon Mubaraq Arisekola, Wang Fu

机构信息

School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, 710061, China.

Department of Cell Biology and Physiology, University of Kansas Medical Centre, Kansas City, KS, 66160, USA.

出版信息

Mol Biol Rep. 2025 May 20;52(1):471. doi: 10.1007/s11033-025-10559-3.


DOI:10.1007/s11033-025-10559-3
PMID:40392380
Abstract

BACKGROUND: Sepsis and uterine corpus endometrial carcinoma (UCEC) share significant immunological and molecular pathways, particularly involving dysregulated inflammatory responses and immune modulation. Although sepsis-induced organ dysfunction is well studied, its role in cancer progression, particularly in UCEC, remains poorly understood. PURPOSE: This study investigated the sepsis-related immune signature (SRIS) C3 in UCEC to uncover its role in tumor progression and metastasis. METHODS: RNA sequencing and clinical data from TCGA and GEO databases were analyzed using R software to identify DESRGs. Survival analysis, GO, KEGG pathway, and GSEA were performed to elucidate C3's biological functions. PPI networks, mutational analysis, methylation profiling, and immune infiltration analysis were conducted using various bioinformatics tools. MTT assays, RT-PCR, qPCR, and wound healing assays were performed to validate C3's function in HEC-1-B. RESULTS: Downregulation of C3 expression in UCEC was associated with enhanced inflammation, immune evasion, and metastatic potential, showing mechanisms observed in sepsis-induced organ dysfunction. Pathway enrichment analysis revealed significant activation of the NF-κB, JAK-STAT, and complement cascades, contributing to a pro-tumorigenic microenvironment. Mutational analysis showed a significant contribution to UCEC development. Protein-protein interaction analysis demonstrated a positive correlation with SRISs. These findings highlight the pivotal role of sepsis-related immune pathways, mainly C3, in driving UCEC progression. CONCLUSION: Understanding the molecular interplay between sepsis-related immune responses and tumor progression may offer novel therapeutic opportunities. Specifically, targeting C3 may provide a new treatment strategy for UCEC patients with a history of sepsis, thereby improving clinical outcomes and guiding personalized therapeutic interventions.

摘要

背景:脓毒症与子宫内膜癌(UCEC)具有显著的免疫和分子通路,尤其涉及炎症反应失调和免疫调节。尽管脓毒症诱导的器官功能障碍已得到充分研究,但其在癌症进展中的作用,特别是在UCEC中的作用,仍知之甚少。 目的:本研究调查了UCEC中与脓毒症相关的免疫特征(SRIS)C3,以揭示其在肿瘤进展和转移中的作用。 方法:使用R软件分析来自TCGA和GEO数据库的RNA测序和临床数据,以识别差异表达的基因(DESRGs)。进行生存分析、基因本体(GO)、京都基因与基因组百科全书(KEGG)通路和基因集富集分析(GSEA),以阐明C3的生物学功能。使用各种生物信息学工具进行蛋白质-蛋白质相互作用(PPI)网络、突变分析、甲基化分析和免疫浸润分析。进行MTT试验、逆转录-聚合酶链反应(RT-PCR)、定量聚合酶链反应(qPCR)和伤口愈合试验,以验证C3在HEC-1-B中的功能。 结果:UCEC中C3表达的下调与炎症增强、免疫逃逸和转移潜能相关,显示出在脓毒症诱导的器官功能障碍中观察到的机制。通路富集分析显示核因子κB(NF-κB)、Janus激酶-信号转导和转录激活因子(JAK-STAT)以及补体级联的显著激活,促成了促肿瘤微环境。突变分析显示对UCEC发展有显著贡献。蛋白质-蛋白质相互作用分析表明与SRIS呈正相关。这些发现突出了脓毒症相关免疫通路,主要是C3,在驱动UCEC进展中的关键作用。 结论:了解脓毒症相关免疫反应与肿瘤进展之间的分子相互作用可能提供新的治疗机会。具体而言,靶向C3可能为有脓毒症病史的UCEC患者提供一种新的治疗策略,从而改善临床结果并指导个性化治疗干预。

相似文献

[1]
Sepsis-related immune signature C3 in endometrial carcinoma: implications for prognosis, tumor progression through bioinformatics and experimental validation.

Mol Biol Rep. 2025-5-20

[2]
Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.

Front Immunol. 2021

[3]
Integrated analysis and experiments uncover the function of disulfidptosis in predicting immunotherapy effectiveness and delineating immune landscapes in uterine corpus endometrial carcinoma.

Front Immunol. 2024

[4]
Cuproptosis-Associated lncRNA Gene Signature Establishes New Prognostic Profile and Predicts Immunotherapy Response in Endometrial Carcinoma.

Biochem Genet. 2024-10

[5]
Prognostic value and clinical significance of IL-33 expression in patients with uterine corpus endometrial carcinoma.

Cytokine. 2025-1

[6]
KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.

Mol Omics. 2022-7-11

[7]
Key wound healing genes as diagnostic biomarkers and therapeutic targets in uterine corpus endometrial carcinoma: an integrated in silico and in vitro study.

Hereditas. 2025-1-21

[8]
UBE2T is a diagnostic and prognostic biomarker for endometrial cancer.

Clin Transl Oncol. 2025-5

[9]
Overexpression of zinc finger DHHC-type containing 1 is associated with poor prognosis and cancer cell growth and metastasis in uterine corpus endometrial carcinoma.

Aging (Albany NY). 2024-6-6

[10]
Comprehensive Analysis of ESRRA in Endometrial Cancer.

Technol Cancer Res Treat. 2021

本文引用的文献

[1]
BUB1 as a novel marker for predicting the immunotherapy efficacy and prognosis of breast cancer.

Transl Cancer Res. 2024-9-30

[2]
DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease.

Clin Mol Hepatol. 2024-10

[3]
Plasma-based proteomic profiling identifies the distinct regulation of proteins in hyperplasia and endometrial cancer.

BMC Cancer. 2024-6-20

[4]
Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases.

Kidney Int Rep. 2023-8-25

[5]
Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.

Front Immunol. 2023

[6]
Glycosyltransferase-related prognostic and diagnostic biomarkers of uterine corpus endometrial carcinoma.

Comput Biol Med. 2023-9

[7]
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2023-2

[8]
PHF6 promotes the progression of endometrial carcinoma by increasing cancer cells growth and decreasing T-cell infiltration.

J Cell Mol Med. 2023-3

[9]
Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review.

Front Immunol. 2022

[10]
Single-cell atlases link macrophages and CD8 T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma.

Theranostics. 2022

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索